The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Therapeutic Use
- 08 Feb 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2018 Planned End Date changed from 1 May 2018 to 31 Dec 2018.